Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Malignant melanoma is one of the most aggressive solid tumors but has low morbidity if treated at an early stage. Over the past decade, the advent of targeted therapy and immunotherapy have productively enriched the treatment options for advanced melanomas and further improved the prognosis. The treatment of melanoma is a rapidly evolving field. In patients with sentinel lymph node (SLN)-positive (SLN+) melanoma, the role of complete lymph node dissection (CLND) is still a matter of debate. Sentinel lymph node biopsy (SLNB) is a staging procedure for melanoma that is routinely offered to patients with tumor thickness ≥1 mm or ≥0.8 mm with additional risk factors and is widely accepted as an important diagnostic and prognostic tool, since SLN+ patients can receive adjuvant targeted treatment or immunotherapy. Currently, the role of CLND has largely been replaced by often recommended adjuvant therapies since their approval. This article provides an overview of sentinel lymph-node surgery in cutaneous melanoma. J Drugs Dermatol. 2022;21(5):510-516. doi:10.36849/JDD.6198.


Dipali Rathod, George Kroumpouzos, Aimilios Lallas, Babar Rao, Dedee F Murrell, Zoe Apalla, Stephan Grabbe, Carmen Loquai, Mohamad Goldust. Critical Review of the Sentinel Lymph Node Surgery in Malignant Melanoma. Journal of drugs in dermatology : JDD. 2022 May 01;21(5):510-516

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35533034

View Full Text